
Pelacarsen and ziltivekimab lowered their targets but not events, and why that matters
Louis shares a physician's commentary on the Lp(a) and inflammation trials presented at AHA: one drug lowered Lp(a) nearly 80% and another sharply cut inflammation, yet event rates matched placebo. The lesson is that measuring and changing a marker does not guarantee benefit, and that the underlying risk factors still matter.

